The results mentioned above indicated that patients with higher risk scores promised to respond to immunotherapy, and immunosuppressants acted on immune checkpoints, such as CTLA4, and PD-L1, and may be applied for immunotherapy in COAD patients. This evidence concerns the gene CD274 and colon adenocarcinoma.